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ABSTRACT
We explored whether engineering of T cell specificity and effector function improves immunotherapy of
solid tumors. Although IL-12 can enhance cancer immunity, a strategy of safe IL-12 delivery without
toxicity is currently lacking. We engineered T cells to express IL-12 controlled by the NFAT promoter
responsive to TCR stimulation, or by the Tet-On promoter responsive to doxycycline. In vivo, NFAT-
engineered T cells caused lethal toxicity, while Tet-engineered T cells were safe in the absence of
doxycycline. Combining gene transfer of the melanoma-specific TRP2-TCR with Tet-IL-12 engineering
revealed that temporal induction of IL-12 was essential to inhibit the growth of B16F10 melanoma
tumors. Induced IL-12 increased the number of tumor-infiltrating T cells and also prevented the down-
modulation of the TRP2-TCR and the associated up-regulation of the PD1 marker that was observed in
the absence of IL-12. In addition, temporal induction of IL-12 expression also increased the number of
plasmacytoid DC in the tumor micro-environment. We show that repeated induction of IL-12 can be
used to enhance control of tumor growth without encountering systemic toxicity. The observation that
TCR engineering combined with Tet-regulated IL-12 expression can achieve tumor immunity without
the side effects that are usually associated with the in vivo use of IL-12 warrants translation of this
concept into the clinic.
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The genetic engineering T cell specificity with chimeric antigen
receptors (CARs) or T cell receptors (TCRs) has provided
a robust platform for directing T cell immunity towards defined
cancer antigens.1–3 Dramatic clinical benefits have been seen
with CAR-engineered T cells specific for CD19, a cancer-
associated antigen present on most B-lineage leukemias.4,5 In
contrast to leukemias, solid cancers establish a complex tumor
stromal environment consisting of new blood vessels, mesench-
ymal cells and hematopoietic cells including myeloid derived
suppressor cells. The establishment of an immune suppressive
micro-environment is one of the mechanisms promoting escape
of developing tumours from natural immune surveillance.6,7
IL-12 is a potent immune stimulatory cytokine capable of
inducing pro-inflammatory Th1 and Th17 immune
responses.8 Murine models have revealed that IL-12 delivery
to sites of tumor growth can convert myeloid suppressor cells
into immune-stimulatory cells and also activate local macro-
phages and NK cells to contribute to tumor immunity.9,10
While adoptive transfer of tumor-specific T cells engineered
to express IL-12 constitutively resulted in improved tumor
protection, this approach also carried a high risk of IL-12
mediated toxicity, as was previously seen in patients treated
by administration of recombinant IL-12.11 Hence, several
groups have explored antigen-specific T cell delivery of IL-
12 to tumors using the DNA binding sites of the nuclear
factor of activated T cells (NFAT) combined with a minimal
IL-2 promoter.9,12,13 Upon stimulation of G-protein-coupled
cell surface receptors or tyrosine-coupled receptors, such as
TCRs, the calcium-regulated NFAT proteins translocate to the
nucleus where, in combination with other transcription fac-
tors, they activate expression of genes containing NFAT bind-
ing sites.14 Although murine models have demonstrated that
NFAT-regulated IL-12 expression in tumor-specific T cells
resulted in enhanced tumor immunity and reduced toxicity,
recent clinical trials in melanoma showed that patient T cells
engineered with the same NFAT-IL-12 construct caused
unacceptable toxicity that required termination of the trial.15
The purpose of this study was to explore whether the Tet-
On system could be used to generate antigen-specific T cells
with tightly controlled IL-12 expression.16 We demonstrate
that adoptive transfer of T cells with Tet-regulated IL-12 is
safe in the absence of doxycycline induction, while ‘leaked’
expression by T cells with NFAT-regulated IL-12 expression
caused lethal toxicity. Transient induction of IL-12 was suf-
ficient to reprogram the tumor micro-environment, boost
the numbers of tumor-infiltrating T cells with reduced
expression of PD1, which resulted in improved tumor
protection.
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Results
Genetic engineering using TCR and IL-12 gene constructs
In order to test the most effective way of combining TCR gene
transfer with regulated IL-12 expression, we generated several
retroviral constructs containing: i) TCR alpha/beta chains
with truncated CD19 as marker for transduction; ii) constitu-
tively expressed IL-12 with GFP as marker; iii) NFAT-
regulated IL-12 with GFP as marker; iv) and IL-12 regulated
by the Tet transactivator that required the presence of dox-
ycycline (Dox) to activate expression from the tet-O7 promo-
ter (Figure 1(a)). In this vector the Q8 marker (truncated
CD34) served to identify transduced T cells and GFP served
as marker for induced IL-12 expression.
In vitro analysis of engineered T cells
In a first set of validation experiments primary mouse T cells
were transduced with the Tet-IL-12 construct, or with an iden-
tical GFP vector control (VC) construct in which IL-12 was
deleted. In the absence of Dox, staining with anti-CD34 (Q8)
antibodies revealed that both vectors transduced more than 80%
of T cells (Figure 1(b)). When Dox was added to the transduced
primary T cells, most but not all Q8-positive cells started to
express high levels of GFP. Intracellular IL-12 staining was
used to demonstrate that all GFP-positive cells transduced with
the Tet-IL-12 vector also expressed IL-12, while all GFP-negative
cells were negative for IL-12. This indicated that GFP was
a reliable marker to identify IL-12 producing cells. The control
of expression by Dox was effective as no intracellular IL-12 was
detectable when transduced cells were not exposed to Dox
(Figure 1(b)). The transduction of primary mouse T cells with
the NFAT-IL-12-GFP construct (Figure 1(a)) revealed that
a large proportion of transduced cells expressed GFP in the
absence of TCR stimulation (Figure 1(c)). As expected, the GFP-
positive cells also expressed IL-12 as determined by intracellular
cytokine staining (not shown). Together the data indicated that
freshly transduced mouse T cells displayed robust control of
GFP/IL-12 expression using the Tet regulation system, but not
the NFAT system.
In the next set of experiments, we tested how Dox-induced
IL-12 expression affected the antigen-specific response of TCR
transduced primary T cells. C57BL/6 T cells were transduced
with the F5-TCR specific for an H2-Db-presented peptide of the
influenza nucleoprotein (NP). The F5-TCR vector was trans-
ferred into T cells together with the vector containing Tet-IL-12
(TTCR+iIL-12) or the control vector lacking IL-12 (TTCR+iGFP).
Transduced T cells were then stimulated in the absence or
presence of Dox with EL4 control cells or EL4-NP expressing
the TCR-recognized target antigen. Figure 1(d) shows that more
than 35% of T cells transduced with the F5-TCR and the vector
control construct produced TNFα when stimulated with EL4-
NP, and approximately 20% of T cells produced TNFα as well as
IFNγ. As expected, the pattern of cytokine production was very
similar in the absence and presence of Dox. However, the pattern
of cytokine production was markedly different for T cells trans-
duced with the F5-TCR and the Tet-IL-12 vector. All T cells
responding to the NP antigen produced high levels of IFNγ and
TNFα. The Tet-IL-12 vector increased the level of antigen-
specific IFNγ production (measured by MFI) by nearly 10-fold
compared to T cells transduced with TCR and GFP control
vector (Figure 1(d)). This is consistent with the Th1-polarising
effects of IL-12.17 However, in the absence of Dox we observed
a similar enhancement of IFNγ production, suggesting leaked
IL-12 expression despite the lack of detectable IL-12 by intracel-
lular staining (Figure 1(b)). We therefore tested culture super-
natant of transduced primary T cells for detachable IL-12
secreted over a 24 h period, which revealed low level of IL-12
in the absence of Dox which was strongly increase in the pre-
sence of Dox (Figure 1(e)).
In vivo safety assessment
The next set of experiments explored the in vivo safety profile of
engineered T cells expressing IL-12. Primary T cells from
C57BL/6 mice were transduced with retroviral constructs
expressing IL-12 constitutively or controlled by the Tet-On or
byNFAT regulatory elements. In order tomimic an adoptive cell
therapy setting, non-myeloablative conditioning was used prior
to adoptive transfer of 5 × 105 transduced T cells into recipient
mice. T cells expressing IL-12 constitutively caused acute weight
loss of more than 20%, at which point the animals had to be
sacrificed according to UK Home Office regulations (Figure 1
(f)). The adoptive transfer of 5 × 105 T cells containing the Tet-IL
-12 construct caused similar acute weight loss in animals receiv-
ing Dox, but not in control animals that were not treated with
Dox (Figure 1(g)). This indicated that the ‘leaked’ IL-12 expres-
sion detected in vitro (Figure 1(e)) did not cause IL-12 driven
weight loss in vivo. In contrast, adoptive transfer of 5 × 105
T cells containing the NFAT-IL-12 construct caused acute
weight loss in the absence of TCR stimulation (Figure 1(g)).
Finally, we tested whether short-term IL-12 induction was asso-
ciated with in vivo toxicity. On day 4 after adoptive transfer of
Tet-IL-12 T cells animals received Dox for 3 consecutive days,
and the analysis of blood samples indicated that at day 3 after
Dox administration 83% of transferred Thy1.1 T cells expressed
GFP, followed by a rapid decline 24 h after Dox discontinuation
(Figure 1(h)). No GFP expression was detectable in transferred
Thy1.1 T cells from mice that did not receive Dox (Figure 1(h),
top panels). Importantly, temporal IL-12 expression did not
result in detectable weight loss (Figure 1(h), bottom). Together,
these experiments indicated that Tet-regulated IL-12 expression
was safe in vivo, and that transient administration of Dox effi-
ciently induced IL-12 expression in the majority of engineered
T cells but was insufficient to cause toxicity.
Analysis of tumor infiltrating T cells
To explore the role of IL-12 in tumor immunity, C57BL/6
mice with established B16F10 tumors were conditioned with
4Gy total body irradiation followed by adoptive T cell trans-
fer. T cells were engineered to express the TRP2-TCR (specific
for tyrosinase-related-protein) or Tet-IL-12 or TRP2-TCR as
well as Tet-IL-12. Due to the observed fatal toxicity, vectors
expressing constitutive IL-12 and NFAT-IL-12 were not tested
in the tumor setting. The “non-toxic” 3-day Dox administra-
tion was used to assess the effect of temporal IL-12 induction
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Figure 1. Design of IL-12 and TCR vectors and in vitro validation.
(a) Diagrams representing the molecular structure of the retroviral vectors. IRES; internal ribosome entry site, LTR; long terminal repeat, GFP; green fluorescent protein, NFAT;
nuclear factor activated T cells. (b) Anti-CD3/CD28-activated splenocytes were transduced with the Tet-IL-12 construct (Tet-IL-12) or vector control (VC) construct containing
GFP only (Tet-GFP), and treated with Dox (1 µg/ml) overnight or left untreated. Representative flow cytometry plots showing the expression of Q8 and GFP in transduced
T cells demonstrating the transduction efficacy and the level of induction in the presence and absence of Dox. Representative histogram overlay showing intracellular IL-12
staining in GFP-positive (induced) and GFP-negative (non-induced) cells after 4hrs treatment with BFA. The experiments were done at least 3 times with similar results. (c)
Anti-CD3/CD28-activated splenocytes were transducedwith NFAT-IL-12 construct ormock-transduced and analyzed by flow cytometry for GFP expression the following day.
(d) Representative flow cytometry plots depicting intracellular IFNγ and TNFα staining of T cells transduced with NP-specific F5-TCR and either Tet-IL-12 (TTCR+iIL-12) or Tet-
GFP vector control (TTCR+iGFP), and stimulated with EL4 (control) or EL4-NP tumor cells expressing the cognate antigen for 4hrs in the presence and absence of Dox. Dot plots
show live-gated TCR-expressing cells (CD19+). Data shown represents at least 3 independent experiments. (e) Measurements of IL-12 secretion in culture supernatant of
transduced T cells by enzyme-linked immunosorbent assay (ELISA). Graph shows mean ± SEM of duplicate values from two experiments. (f) Mean of body weight
measurements over time post transfer of 5 × 105 TcIL-12 or Tmock transduced cells into sublethally irradiated (4Gy) recipient mice; baseline is 100%. n = 3 mice per group. (g)
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on tumor immunity (Figure 2(a)). Five days after adoptive cell
therapy the numbers and phenotype of T cells and myeloid
cells in the B16F10 tumors were analyzed.
The TRP2-TCRwas inserted into our retroviral vector that also
contained the truncated CD19 as a marker of transduction effi-
cacy (Figure 1(a)). When primary mouse T cells were transduced
with this construct, the level of TRP2-TCR expression correlated
with the level of CD19 expression (suppl Fig 1A). Double trans-
duction with the TCR and the Tet-IL-12 vectors generated a large
number of T cells expressing both CD19/TCR and the Q8/CD34
marker (suppl Fig 1B). For the in vivo experiments 2 × 106 T cells
expressing the TRP2-TCR only, or 2 × 106 cells expressing both
TCR plus the Q8/CD34 were adoptively transferred into B16F10
tumor bearing mice. T cells engineered with only the TRP2-TCR
showed modest enrichment in the tumor compared to mock
transduced T cells (Figure 2(b)). However, dramatically increased
tumor infiltration was observed after adoptive transfer of T cells
engineered with the TRP2-TCR and Tet-IL-12. While Tet-IL-12
alone also increased T cell frequency, the combination of mela-
noma-specificity and induced IL-12 expression was most potent
in boosting the frequency of adoptively transferred T cells in the
tumor (Figure 2(b)). Figure 2(c) demonstrated that IL-12 pro-
moted the selective accumulation of transduced CD19-positive
T cells in the tumor, which was associated with a reduction in the
frequency of the CD19-positive T cells in spleen and lymph nodes.
This suggested that selective recruitment of TRP2-specific T cells
from the periphery into the tumor was one factor by which IL-12
increased the frequency of antigen-specific T cells in the tumor
microenvironment. In addition to increasing T cell numbers, IL-
12 also mediated enhanced expression level of CD19/TCR in
tumor-resident T cells compared to T cells found in the spleen
and lymph nodes (Figure 2(c,d)). In contrast, TRP2-TCR engi-
neered T cells that were unable to produce IL-12 displayed
a phenotype that was characterized by reduced TCR levels and
elevated expression of the PD1 marker (Figure 2(e)). The fre-
quency of TCR-low/PD1-high T cells was high when T cells were
unable to produce IL-12, and was substantially reduced by the
temporal induction of IL-12 (Figure 2(e)). Correspondingly, IL-12
increased the frequency of TCR-high/PD1-low T cells in the
tumor micro-environment. Together, these data indicated that
transient expression of IL-12 in the first 3 days after adoptive
cell therapy increased the accumulation of T cells expressing high
levels of TCR and low levels of PD1 in the tumor.
Analysis of tumor infiltrating myeloid cells
Tumors ofmice treated as described above with T cells transduced
with TCR or Tet-IL-12 or TCR plus Tet-IL-12 were analyzed for
the presence of dendritic cells, macrophages and CD11bpos/Gr1low
myeloid suppressor cells using the staining panels shown in Figure
3(a). As described previously, IL-12 reduced the relative frequency
and absolute numbers of CD11b+/Gr1lowmyeloid suppressor cells
(Figure 3(b)). However, we also observed an IL-12 dependent
increase in CD11b−/Gr1+ cells. Further analysis of this population
of cells showed B220 expression combined with low/intermediate
levels of CD11c and MHC class II (I-Ab), a phenotype that is
characteristic of murine plasmacytoid DC (Figure 3(c)). The
frequency of these plasmacytoid DC in the tumor was substan-
tially increased when T cells were engineered to express the TRP2-
TCR and Tet-IL-12 (Figure 3(c)).
Tumor inhibition by IL-12
Mice with establish B16F10 tumors were conditioned and then
treated by adoptive transfer of T cells expressing TRP2-TCR or
TRP2-TCR plus Tet-IL-12. T cells engineered with only Tet-IL
-12 were used to reveal non-antigen-specific effects of IL-12.
Dox-induction of IL-12 was either done once in the first
3 days, or twice in the first 3 days and again on day 10–13 after
T cell transfer (Figure 4(a)). Figure 4(b) shows that T cells
expressing TCR were unable to inhibit the growth of B16F10
tumors. T cells engineered with Tet-IL-12 mediated a small
reduction in tumor growth, but the most pronounced inhibition
was seen with T cells expressing TCR plus Tet-IL-12. The more
effective growth inhibition correlated with the improved survival
of mice treated with TCR+ Tet-IL-12 T cells compared to T cell
expressing only TCR or only Tet-IL-12 (Figure 4(c)). However,
despite improved protection, the T cell mediated immunity was
insufficient to prevent tumor progression.We testedwhether the
B16F10 tumors that grew in mice treated with TCR+ Tet-IL
-12 T cells were escape variants that had lost the TCR-
recognized target antigen. To address this, tumors of T cell
treated mice were reisolated and tested for their ability to stimu-
late effector function of TRP-TCR transduced T cells. Figure 4
(d) demonstrates that all reisolated tumors were not antigen-
escape variants and stimulated TCR transduced T cells as effec-
tively as B16F10 cells that were cultured in vitro for the same
time period as tumors that grew in vivo.
In a final set of experiments, we tested whether repeated IL-
12 induction could further enhance the level of tumor protec-
tion. Figure 4(e) demonstrates that repeated IL-12 induction
at day 10–13 after adoptive cell transfer was more effective in
inhibiting tumor growth than a single cycle of IL-12 induction
during the initial 3 days following T cell transfer. Similarly, two
cycles of IL-12 induction resulted in substantial survival bene-
fits by nearly doubling the survival time compared with mice
treated with engineered T cells expressing only the TRP2-TCR
(Figure 4(e)). At the time when mice reached lethal tumor
Mean of body weight measurements over time of mice receiving 5 × 105 Tet-IL-12 or NFAT-IL-12 transduced T cells. Mice received Tet-IL-12 transduced T cells were split into
two cohorts: one received Dox (2mg/ml) in drinking water (+ Dox) and the other cohort left untreated (-Dox). n = 5 mice per group. (h) Kinetics of transient IL-12 induction
in vivo. C57BL/6 mice (Thy1.2+) were sublethally irradiated (4Gy) and injected intravenously with 5 × 105 Tet-IL-12 transduced T cells (Thy1.1+). On day 4 post T cell transfer,
mice were split into two groups, one group received Dox-containing water (2mg/ml) for 3 consecutive days and the other group left untreated. Blood samples were
obtained at 24hrs, 48hrs and 72hrs following Dox administration, and 24hrs following Dox withdrawal. Representative flow cytometry plots showing the levels of GFP
expression. Cells were pre-gated on PI- singlet Thy1.1+ lymphocytes. n = 4 mice (-Dox); n = 6 mice (+ Dox) (top). Mean of body weight measurements over time showing
lack of toxicity with temporal Dox induction post transfer of 5 × 105 Tet-IL-12 transduced cells into sublethally irradiated (4Gy) recipient mice. Mice received Tet-IL-12
transduced T cells were split into two cohorts: one received Dox (2mg/ml) in drinking water (+ Dox) for 3 days and the other cohort left untreated (-Dox). Graph showsmean
± SEM. n = 5 mice per group (bottom).
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Figure 2. Temporal induction of IL-12 in TCR-engineered T cells increases the numbers of T cells in the tumor and prevents PD-1 upregulation.
(a) Experimental setup. C57BL/6 female mice (Thy1.2+) were inoculated subcutaneously with 5 × 105 B16 melanoma cells. 10 days later, mice were sublethally
irradiated with 4Gy TBI 3-4hrs prior receiving intravenous injection of 2 × 106 T cells (Thy1.1+) that were transduced with TRP2-TCR (TTCR), Tet-IL-12 (TiIL-12), TRP2-TCR
+ Tet-IL-12 (TTCR+iIL-12), or mock-transduced T cells (Tmock). All mice received Dox (2mg/ml) in drinking water 2–3 days prior receiving T cell infusion and kept on Dox
water for another 3 days. Tumors, spleens and lymph nodes were harvested on day 5 after the adoptive transfer and analyzed by flow cytometry. (b) Representative
dot plots showing the percentage of transferred cells (Thy1.1+) (top) and pooled summary data (bottom). Cells were pre-gated on live-singlet lymphocytes. Symbols
represent individual mice and bars indicate group averages. P values: TTCR versus TTCR+iIL-12 transduced cells and TiIL-12 versus TTCR+iIL-12 transduced cells; p < 0.0001.
(c) Relative accumulation of TCR-expressing cells (CD19+) in tumor, spleen and draining lymph nodes (DLN) 5 days post T cell transfer. Cells were pre-gated on live-
singlet transferred Thy1.1+ T cells. Data shown are cumulative results from at least two independent experiments. P values for the frequency of TCR+ cells: TTCR versus
pre-injection in the tumor, spleen and DLN; p > 0.05, TTCR+iIL-12 versus pre-injection in the tumor; p = 0.0010, spleen; p = 0.0020 and DLN; p = 0.0049. P values for
CD19 MFI: TTCR versus TTCR+iIL-12 in the tumor; p < 0.0001, spleen and DLN; p > 0.05. Symbols represent individual mice (TTCR, n = 8 and TTCR+iIL-12, n = 11). (d)
Representative flow cytometry plots depicting the percentage of TCR-expressing cells (CD19+) and mean fluorescence intensity (MFI) of CD19 within the adoptively
transferred Thy1.1+ T cells. Cells were pre-gated on live-singlet lymphocytes. (e) Representative flow cytometry plots depicting PD-1 staining profile of TCR-
expressing cells (Vβ3+) in the tumor which divided them into two populations: Vβ3hi PD-1lo and Vβ3lo PD-1hi T cells (top) and bar charts representing summary data
pooled from two independent experiments (bottom). P values: percentage of Vβ3hi PD-1lo T cells in TTCR versus TTCR+iIL-12; p < 0.0001, percentage of Vβ3
lo PD-1hi
T cells in TTCR versus TTCR+iIL-12; p = 0.0011.
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Figure 3. Transient IL-12 induction changes the myeloid cell composition of the tumor microenvironment.
C57BL/6 female mice bearing subcutaneous melanoma for 10 days were sublethally irradiated with 4Gy TBI prior to adoptive T cell transfer of Tmock, TTCR, TiIL-12 or
TTCR+iIL-12 transduced T cells. All mice received Dox-containing water (2mg/ml) 2–3 days prior receiving T cell infusion and kept on Dox water for another 3 days.
Tumor infiltrating cells were harvested on day 5 post T cell transfer and analyzed by flow cytometry. (a) Gating strategy. Using forward scatter (FSC) and side scatter
(SSC), tumor cells (FSC/SSC high), granulocytes (SSC intermediate) and lymphocytes (FSC/SSC low) were identified. PI− singlet granulocytes were assessed for their
surface expression of CD11b, CD11c, F4/80 and Gr-1 to identify different myeloid-derived cell populations including: CD11b+CD11c+; dendritic cells (DCs), CD11b+F4/
80+; macrophages (MQs) and CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs), including monocytic MDSCs (Gr-1mid; MDSC-M) and granulocytic MDSCs (Gr-1hi;
MDSC-G). (b) Representative dot plots showing tumor infiltrating myeloid-derived cells 5 days after the adoptive T cell transfer (left) and pooled summary data
(right). Cells were pre-gated on live-singlet granulocytes. Graphs are showing mean ± SEM. P values: frequency of DCs in mice treated with TTCR versus TTCR+iIL-12; p
= 0.0001, frequency of MQs in mice treated with TTCR versus TTCR+iIL-12; p = 0.0001, TTCR+iIL-12 versus TiIL-12; p = 0.0008, frequency of MDSCs in mice treated with TTCR
versus TTCR+iIL-12; p = 0.0003, frequency of CD11b
−Gr-1+ in mice treated with TTCR versus TTCR+iIL-12; p = 0.0001, TTCR+iIL-12 versus TiIL-12; p = 0.0432, total number of
DCs in mice treated with TTCR versus TTCR+iIL-12; p = 0.0195, TTCR+iIL-12 versus TiIL-12; p = 0.0249, total number of MQs in mice treated with TTCR versus TTCR+iIL-12; p
= 0.0441, TTCR+iIL-12 versus TiIL-12; p = 0.0091, total number of CD11b
−Gr-1+ in mice treated with TTCR versus TTCR+iIL-12; p = 0.0031. Data shown are cumulative results
of two independent experiments. Number of mice per group: Tmock, n = 10; TTCR, n = 7; TiIL-12, n = 8; TTCR+iIL-12, n = 11. (c) Identification of pDC subset infiltrating the
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burden, we analyzed the number and phenotype of adoptively
transferred T cells. This revealed that the T cell frequency in the
tumors, spleen and bone marrow was similar in mice treated
with TCR-only, or TCR+ Tet-IL-12 T cells (suppl. Fig 2),
although the average time from adoptive transfer to lethal
tumor burden was 25 days for the TCR-only group, and 35 or
45 days for the TCR+ Tet-IL-12 group (Figure 4(c)).
Furthermore, the CD62L, CD127, PD-1 and annexinV expres-
sion profiles of tumor infiltrating T cells were similar in all
groups (suppl. Fig 3C and E). In contrast, proliferation of
tumor infiltrating T cells, as assessed by Ki67 staining,
decreased over time from 40% at day 25 to 20% at day 45
(suppl. Fig 3D). Together, this data suggested that tumor infil-
trating T cells developed over time a partial hypo-
responsiveness that was not prevented by the temporal induc-
tion of IL-12.
Discussion
Although IL-12 is a potent immune stimulatory cytokine, its
clinical application to boost immunity in cancer patients has
been limited by severe side effects including the death of two
patients in early clinical trials.18 Subsequent trials in patients
with head and neck cancer involved the injection of recombi-
nant IL-12 at the tumor site, which was associated with high
level of systemic IFNγ production and substantial toxicity
necessitating the termination of the clinical trial.11 Similarly,
toxicity was seen in melanoma patients treated with autolo-
gous tumor infiltrating lymphocytes (TIL) that were geneti-
cally engineered to express IL-12 under the control of NFAT
regulatory elements.15 In this melanoma trial, T cell doses that
mediated tumor regression also induced severe toxicity in 5
out of 16 treated patients, possibly caused by high level
systemic IL-12 and IFNγ that was detectable in the serum of
patients. This trial experience has indicated that NFAT-
regulated IL-12 expression is not sufficiently safe to achieve
tumor immunity without substantial toxicity in patients.
This was somewhat surprising, as previous studies in mur-
ine systems did not report systemic toxicity with NFAT regu-
lated IL-12 expression. In one study, human T cells
engineered to express NFAT-regulated human IL-12 and
a CAR specific for human carcinco-embryonic antigen
(CEA) were tested in immune-deficient mice bearing human
CEA-positive tumors.9 The lack of detectable toxicity in these
studies may be related to the relative poor expansion and
survival of human T cells in immune-deficient mice, and to
a species barrier impairing the biological activity of human
IL-12 in mice. However, similar to our work reported here,
Zhang and colleagues have used the B16 melanoma model for
adoptive therapy with TCR-transgenic T cells engineered to
express IL-12 in an NFAT-regulated fashion.12 In these stu-
dies, the adoptive transfer of up to 3 million TCR transgenic
T cells specific for the pmel melanoma antigen provided
protection against B16 tumors in the absence of detectable
toxicity. In contrast, we observed lethal toxicity when
2 million T cells containing the NFAT IL-12 construct were
transferred into conditioned mice. Experimental differences
might contribute to the observed differences in the outcome.
In our studies 2 million T cells that were successfully trans-
duced with the NFAT IL-12 construct were adoptively trans-
ferred into mice, compared to a total dose of 3 million pmel
T cells where the transduction efficiency with NFAT IL-12
was not reported. It is therefore possible that the total number
of NFAT IL-12 engineered T cells in our study was greater
than the maximal dose reported by Zhang et al. In addition, it
is conceivable that the ‘natural’ TCR repertoire of bulk T cells
used in our studies may contain self-reactive T cells that are
absent in the repertoire of pmel-TCR transgenic mice. In this
case, the recognition of self-antigens might trigger increased
IL-12 release by NFAT regulated bulk T cells but not by pmel-
TCR transgenic T cells. Irrespective of the differences between
the two murine studies, the clinical experience with NFAT IL-
12 transduced TIL in melanoma patients is in line with the
substantial toxicity risk observed in this report.15 Similarly
a recent study in HLA-A0201 transgenic mice bearing HLA-
transfected B16 tumors showed that adoptive transfer of
T cells with NFAT regulated IL-12 expression resulted in
severe toxicity in recipient mice.19
We found that Dox is efficient in regulating IL-12 expres-
sion in vivo. Although the in vitro studies revealed low IL-12
leakage in the absence of Dox, this did not cause toxicity
in vivo, which was strictly dependent on the continued
administration of Dox after T cell transfer. Adding Dox to
the drinking water efficiently induced IL-12 production
within 24 hours and returned to baseline 24–48 hours after
removal of Dox from the water. Surprisingly, administration
of Dox in the first 3 days after T cell transfer was sufficient to
increase T cell numbers in the tumors, reduce expression of
the PD1 exhaustion marker and change the myeloid cell
composition of the tumor microenvironment, including an
increase in the numbers of plasmacytoid DCs. We did not see
an IL-12 mediated increase in macrophages in the tumor,
which was seen when NFAT IL-12 human T cells were tested
in immune-deficient mice.9 In line with the report by Kerkar
et al. using murine T cells expressing IL-12 constitutively, we
also found a reduction in the number of tumor resident
macrophages and myeloid derived suppressor cells after tran-
sient IL-12 induction in the first 3 days after T cell transfer.10
The transient expression of IL-12 may not only reduce the
risk of toxicity but also avoid the negative effects of IL-12 on
T cells. For example, studies of human T cells have shown that
continued exposure to high level IL-12 can induce exhaustion
markers and reduce T cell effector function.20 Similarly,
in vivo murine experiments indicated that low dose
tumor at day 5 following T cell transfer. CD11b−Gr-1+ population were analyzed for the surface expression of CD11c, B220 and MHC class II molecules (I-Ab).
Representative plots showing tumor-infiltrating pDCs in mice treated with TiIL-12 and TTCR+iIL-12 cells (left) and pooled summary data for the frequency of
B220+CD11clo/mid cells pre-gated on live-singlet CD11b−Gr-1+ granulocytes in mice treated with Tmock, TTCR, TiIL-12 or TTCR+iIL-12 transduced T cells (right). Graphs
are showing mean ± SEM. P values: frequency of pDCs in mice treated with TTCR versus TTCR+iIL-12 and TiIL-12 versus TTCR+iIL-12; p = 0.0159, total number of pDCs in
mice treated with TTCR versus TTCR+iIL-12; p = 0.015.
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recombinant IL-12 was able to enhance viral immunity, while
high doses were ineffective.21 In the recent clinical trial with
NFAT IL-12 engineered TIL, the authors observed poor per-
sistence of the transferred T cells and speculated that this
might be due to the inhibition of T cell proliferation by high
level IL-12 production. It is therefore possible that transient
IL-12 expression may avoid some of the negative effects that
are associated with continued exposure of T cells to IL-12. In
Figure 4. IL-12 overexpression in TCR-engineered T cells delay the development of lethal tumor burden in B16 melanoma-bearing mice.
(a) Experimental setup. C57BL/6 (Thy1.2+) female mice bearing 10 days B16F10 melanoma were sublethally irradiated and injected intravenously with 2 × 106
transduced T cells (Thy1.1+) including TTCR, TiIL-12, TTCR+iIL-12 or Tmock cells. All mice received Dox (2mg/ml) in drinking water 2–3 days before T cell transfer and kept
on Dox for another 3 days. In another set of experiments, mice that were treated with TTCR+iIL-12 cells were split into two cohorts: one group had single induction of
IL-12 (at d10) and the other group had double induction of IL-12 (at d10 and d20 post tumor injection). (b) Tumor size over time post T cell transfer until mice
reached lethal tumor burden. (c) Kaplan-Meyer survival plots of mice treated with TTCR, TiIL-12, TTCR+iIL-12 or Tmock cells. P values: Tmock versus TTCR or TiIL-12; p > 0.05
(ns), TTCR versus TTCR+iIL-12; p < 0.0001. Data shown in B and C are cumulative results of at least two independent experiments. Number of mice per group: Tmock, n
= 10; TTCR, n = 10; TiIL-12, n = 9; TTCR+iIL-12, n = 11. (d) B16F10 tumors were re-isolated from mice treated with TTCR, TTCR+iIL-12 or Tmock cells at the time point when
mice reached lethal tumor burden. The tumor cells were pre-treated overnight with IFNγ-containing medium and co-cultured with TRP2-TCR-transdcued T cells
(CD19; TCR reporter marker) for 5hrs in the presence of BFA. Representative dot plots showing antigen-specific production of IFNγ by TCR-positive cells. Parental
B16F10 melanoma cells and EL4-NP tumor cells were used as a positive and negative controls, respectively. Cells were pre-gated on live-singlet lymphocytes. (e)
B16F10 tumor growth kinetics until mice reached lethal tumor burden (left) and Kaplan-Meyer survival plot of mice received TTCR, TTCR+iIL-12 (1x Dox; single
induction), TTCR+iIL-12 (2x Dox; double induction) or Tmock transduced T cells. P values: TTCR versus TTCR+iIL-12 (1x Dox); p = 0.0002, TTCR versus TTCR+iIL-12 (2x Dox);
p < 0.0001, TTCR+iIL-12 (1x Dox) versus TTCR+iIL-12 (2x Dox); p = 0.0004 (right). Data shown represent pooled data from three independent experiments. Number of
mice per group: Tmock, n = 15; TTCR, n = 17; TTCR+iIL-12 (1x Dox), n = 12; TTCR+iIL-12 (2x Dox), n = 13.
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our experiments we found that transient IL-12 induction in
engineered T cells increased the numbers of T cells in the
tumor and also prevented the up-regulation of the PD1
exhaustion marker. We do not fully understand the mechan-
isms by with IL-12 prevented/reversed the expression of PD1.
A recent human study has shown that IL-12 can function as
3rd signal to restore functional activity of exhausted human
T cells.22 In this study, improved T cell function was asso-
ciated with IL-12 mediated down-modulation of PD1, which
is similar to the IL-12 effect observed in our study.
Our data suggest that the IL-12 driven accumulation of T cells
in the tumor mirco-environment was partly due to selective
recruitment of TCR-positive T cells from spleen and lymph
nodes into the tumor (Figure 2(c)), and partly to an increase in
proliferation of tumor resident T cells as determined by
increased staining for Ki67 (data not shown). It is likely that
the increased numbers of plasmacytoid DC (Figure 3(c))
improved T cell stimulation by cross presentation of B16 mela-
noma antigens to TRP2-postive T cells, although it is difficult to
experimentally dissect the precise role of this DC subset in our
model.
The potential immunogenicity of the bacterially-derived Tet
trans-activator protein could limit the survival of engineered
T cells in vivo. A previous study has identified epitopes in the
trans-activator protein that can be recognized by cytotoxic
T cells.23 In this study vectors were injected into muscle tissue to
achieve expression of the trans-activator protein. The induction of
cytotoxic T cell responses against the identified epitopes was
dependent upon the extent of local inflammation associated with
different vector types, and was not seen when ‘weakly immuno-
genic’AAVvectors were used.23 In our study no vectors were used
in vivo, and it is possible that the expression of the trans-activator
protein in ex-vivo engineered autologous T cells may not be
sufficiently immunogenic to stimulate cytotoxic T cell responses
in vivo.
The Dox-regulated system described here offers the option
to repeat IL-12 expression in vivo at defined time intervals.
We found that two cycles of IL-12 induction were superior to
one cycle in providing tumor protection against B16 mela-
noma. A further advantage of the system described here is
that doxycycline and other tetracylins antibiotics have an
extensive safety track record in patients, facilitating their
clinical use in trials to assess the feasibility, safety and efficacy
of the Dox-regulated IL-12 expression in cancer patients.
Materials and methods
Mice
Female C57BL/6 and C57BL/6 (Thy1.1+) mice used in this study
were bred in-house in the animal facility, a specific pathogen-
free facility, at University College London-based at the Royal
Free Hospital or obtained from Charles Rivers Laboratories. All
animal experiments were performed in accordance with the
United Kingdom Home office regulations.
Cell lines
Phoenix Ecotropic (ECO), an adherent packaging cell lines
(Nolan Laboratory, Stanford, CS, USA), were used to produce
viral supernatants containing retrovirus particles for
transduction of mouse T cells. The ECO cells were maintained
in IMDM supplemented with 10% heat-inactivated fetal calf
serum, 1% of 2 mM L-glutamine and 1% of 100U/ml
Penicillin/Streptomycin.
EL4 is a murine lymphoma cell line (H-2b) and EL4-NP is
a variant stably expressing the influenza A derived nucleoprotein
(NP) peptide (a kind gift from Dr B. Stockinger, National
Institute for Medical Research, London). B16F10 is a murine
melanoma cell line derived from a C57BL/6 mouse developed
melanoma. All tumor cell lines were maintained in RPMI sup-
plemented with 10% heat-inactivated fetal calf serum, 1% of
2 mM L-glutamine and 1% of 100U/ml Penicillin/streptomycin.
Retroviral constructs
The retroviral F5-TCR and TRP2-TCR vectors (pMP71-TCRα-
2A-TCRβ-IRES-CD19), which encodes the TCR α/β chains
linked by 2A sequences, followed by an internal ribosome
entry site (IRES) and truncated CD19 (ΔCD19) as reporter
marker, were modified from pMX-TCRα-IRES-TCRβ (a kind
gift from Prof T. Schumacher, Netherland Cancer Institute,
Amsterdam). These vectors were modified to encode
a truncated CD19 (ΔCD19) that includes the transmembrane
and extracellular domains of mouse CD19 downstream of an
internal ribosome entry site (IRES) sequence. The F5-TCR
recognizes the influenza A virus nucleoprotein (NP366-379) pep-
tide in the context of murine MHC class I (H-2Db). The TRP2-
TCR recognizes the Tyrosinase related protein-2 (TRP2181-188)
in the context of murine MHC class I (H-2Kb). Both TCRs were
codon optimized and have an additional cysteine residue in the
constant region. The retroviral vector expressing constitutive IL-
12 (cIL-12), pMP71-IL-12-IRES-GFP, was generated by cloning
mouse single chain IL-12 containing the p40 and p35 subunits of
IL-12 linked by (Gly4Ser)3 flexible linker, followed by IRES and
green fluorescent protein (GFP) into the pMP71 vector back-
bone. The IL-12p40-(Gly4Ser)3-IL-12p35 was obtained from the
self-inactivating retroviral vector pSIN-(NFAT)6-IL-12-IRES-
GFP under the control of nuclear factor activated T cells
(NFAT)-responsive promoter containing six NFAT-binding
motifs combined with a minimal IL-2 promoter (a kind gift
from Dr T. Schumacher, The Netherlands Cancer Institute and
from Dr H. Abken, University of Cologne).
The pSERS retroviral vectors, all-in-one Tet-On inducible
system, used to regulate the transgene expression16 was modified
to encode mouse single chain IL-12 linked to GFP via
a ribosomal skipping P2A sequence (Tet-IL-12) or GFP alone
(Tet-GFP), which is under the control of tetracyclin-responsive
promoter containing repeats of tet operator sequences fused to
a minimal promoter (Tet-O7). This vector also encodes the
reverse tet-responsive transactivator (rtTA2-M2) which is
fused to a minimal epitope called Q8 (a truncated human
CD34 linked to a CD8 stalk) via a ribosomal skipping foot-and-
mouth disease 2A sequence, and is constitutively expressed by
the human phosphoglycerate kinase (hPGK) promoter.
Retroviral transduction of T cells
For retroviral production, the ECO packaging cells were tran-
siently transfected with the retroviral vectors using FuGENE®
HD transfection reagent (Promega), and viral supernatants were
harvested 48 hours following transfection. For retroviral
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transduction, splenocytes from C57BL/6 female mice were har-
vested and activated with CD3/CD28 antibody coated beads
(Dynabeads-Mouse T cell activator, Gibco). 24 hours later,
activated splenocytes were transduced with the retroviral super-
natants containing the indicated vectors or mock-transduced
using RetroNectin (Takara-Bio-Otsu, Japan)-coated plates.
After spinning the plate at 712g for 90 minutes at 32 C, cells
were cultured in the presence of 20 U/ml IL-2 (Roche).
Flow cytometry
The following monoclonal antibodies (mAbs) were used: anti-
murine Thy1.1 (H1S51), CD19 (ID3), CD11b (M1/70), F4/80
(BM8) supplied by eBiosciences; anti-murine Vβ3 (KJ25), PD-1
‘CD279ʹ (J43), IL-12 (C15.6), IFNγ (XMG1.2), TNFα (MP6-XT
22), CD11c (HL3), Gr-1 ‘Ly-6G and Ly-6C’ (RB6-8C5), B220
(RA3-6B2) and I-Ab (MHCII) (AF6-120.1) supplied by BD
Pharmigen; and anti-human CD34 (QBEND/10) supplied by
AbD Serotec. Single cell suspensions prepared from mouse tis-
sues were initially FC-blocked with anti-mouse CD16/32
(eBiosciences). For intracellular cytokine staining, the BD
Cytofix/Cytoperm™ kit (BD Biosciences) was used. To select
for viable cells, propidium iodide (BD Pharmigen) was used,
and alternatively, Fixable Viability Dye was used when cells were
fixed for intracellular staining. Data were acquired using BD™
LSRII or BD LSRFortessa™ flow cytometers (BD Biosciences) and
analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
Cytokine release assay
Engineered T cells were stimulated and assessed 4–5 days fol-
lowing transduction. Transduced T cells were co-cultured with
tumor cells either EL4 or EL4-NP (in a responder-to-target ratio
of 1:2), and incubated in supplemented RPMI in a 24 well tissue
culture plate. T cells were also stimulated (nonspecifically) with
PMA (50ng/ml) and Ionomycin (1μg/ml) as a positive control
for intracellular cytokine staining. Stimulated T cells were trea-
ted with 10μg/ml BFA (Sigma) at the beginning of the stimula-
tion to block cytokine secretion and were incubated for 4-5hrs
under standard tissue culture conditions. Following the incuba-
tion period, cells were washed and stained with mAbs.
Adoptive transfer and tumor challenge
C57BL/6 (Thy1.2+) female recipient mice at 8–12 weeks of age
were injected subcutaneously (s.c.) with 5 × 105 B16 melanoma
cells. After 10 days, mice were sub-lethally irradiated with 4 Gy
total body irradiation (TBI) and received intravenous (i.v.) injec-
tion of 2 × 106 transduced T cells. Tumors were measured over-
time at different time intervals using a digital caliper; tumor size
was calculated using the following formula (a x b x 3/4, where a is
the horizontal diameter and b is the vertical diameter of the tumor.
Statistical analysis
All statistical analysis was performed using GraphPad Prism soft-
ware version 6.0 (GraphPad Software, USA). To calculate p values
and test for significant differences as specified in the figure legends,
a two-tailedMann-Whitney test or two-tailedWilcoxonmatched-
pairs signed rank testwere utilized. The log-rank (Mantel Cox) test
was utilized for comparison of survival curve. A significant differ-
ence between groups was indicated by a p value of ≤ 0.05
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